Ribociclib (KRYXANA) 200MG Tablet

$2,363.00

Clinical trials have demonstrated the remarkable efficacy of ribociclib in prolonging progression-free survival and improving overall survival rates in patients with HR+/HER2- metastatic breast cancer when used in combination with aromatase inhibitors. It has shown superiority over standard treatments, offering a significant advancement in the management of this disease.

Tag:

Ribociclib KRYXANA

Description

Ribociclib Kryxana FCT 200mg Tablet is a breakthrough medication designed to combat advanced or metastatic breast cancer, specifically hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. Its active ingredient, ribociclib, belongs to a class of drugs known as cyclin-dependent kinase (CDK) 4/6 inhibitors. This innovative therapy offers new hope and improved outcomes for patients confronting this challenging diagnosis.

Key Features:

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: Ribociclib acts as a potent inhibitor of CDK 4/6, key enzymes involved in the regulation of cell cycle progression. By inhibiting CDK 4/6, ribociclib blocks the proliferation of cancer cells and halts tumor growth in HR+/HER2- metastatic breast cancer.
Treatment of HR+/HER2- Metastatic Breast Cancer: Ribociclib Kryxana FCT 200mg Tablet is indicated for use in combination with aromatase inhibitors for the treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer. It represents a pivotal therapy option in the management of this aggressive form of breast cancer.
Oral Administration: Ribociclib Kryxana FCT 200mg Tablet is administered orally once daily, with or without food. The convenient dosing regimen enhances patient compliance and facilitates adherence to treatment.
Efficacy: Clinical trials have demonstrated the remarkable efficacy of ribociclib in prolonging progression-free survival and improving overall survival rates in patients with HR+/HER2- metastatic breast cancer when used in combination with aromatase inhibitors. It has shown superiority over standard treatments, offering a significant advancement in the management of this disease.
Side Effects: Common side effects associated with ribociclib may include neutropenia, leukopenia, fatigue, nausea, and diarrhea. Patients should be closely monitored for adverse reactions, and dose adjustments may be necessary to manage side effects effectively.
Patient Education: Patients prescribed Ribociclib Kryxana FCT 200mg Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
Consultation with Healthcare Provider: Treatment with Ribociclib Kryxana FCT 200mg Tablet should be initiated and monitored by a qualified oncologist experienced in the management of breast cancer. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
Access and Affordability: Efforts should be made to ensure equitable access to Ribociclib Kryxana FCT 200mg Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to innovative medications is crucial to improve patient outcomes and quality of life.